Stockreport

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics, Inc.  (RLAY) 
PDF Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to [Read more]